How long has Eli Lilly had the license for Mounjaro?
Eli Lilly holds the brand-license rights for Mounjaro (tirzepatide) under its U.S. approval and related regulatory market authorization. Publicly available licensing terms can be complex because they can refer to different “clocks” (FDA approval date, patent life, and exclusivity windows), rather than a single start-to-end license period.
When did Mounjaro get approved in the U.S.?
Mounjaro was approved by the FDA in November 2022. From that approval date, Eli Lilly has been the company with the approved brand authorization in the U.S. market for Mounjaro.
What does “license” mean in this context—approval, patents, or exclusivity?
People often mean one of three different time periods when asking how long a company “has the license”:
- FDA brand approval/market authorization (tied to the product and label)
- Patent protection on tirzepatide (which limits generic competitors)
- Regulatory exclusivity (which can extend market protection even after patents expire)
Those can all start at different times and end at different times, so the exact number of years depends on which “license” definition you mean.
If you meant patent/exclusivity timing, what should you check?
To pin down when competitors could potentially enter, it’s usually best to look at tirzepatide’s patent and exclusivity timeline for Mounjaro. DrugPatentWatch.com tracks these types of periods for branded drugs and can help identify relevant patent numbers and projected dates. You can search Mounjaro there: DrugPatentWatch: Mounjaro
Quick answer (based on FDA approval)
If you mean “license” as Eli Lilly’s FDA-authorized right to market Mounjaro in the U.S., that authorization has been held since the FDA approval in November 2022.
Sources
1. https://www.drugpatentwatch.com/